FDA to Warn J&J Vaccine Can Increase Guillain-Barré Risk: Media

News

Find the latest COVID-19 news and guidance in Medscape’s  Coronavirus Resource Center.

People receiving the Johnson and Johnson COVID-19 vaccine could be at increased risk for developing Guillain-Barré syndrome, the US Food and Drug Administration (FDA) is expected to announce as early as tomorrow, according to multiple media reports.

While the FDA is projected to add the new warning to the labeling for the vaccine, the agency still calculates the benefit of vaccination with the J&J product continues to outweigh the risk. Benefits include protection against the Delta variant and serious COVID-19 outcomes.

More than 100 cases of Guillain-Barré reported to the Vaccine Adverse Event Reporting System, a federal program for reporting vaccine issues, spurred the FDA to act.

Men and people older than 50 appear to be at highest risk, according to reports of a July 12 Centers for Disease Control and Prevention (CDC) statement. The CDC also revealed that most cases occur about 2 weeks following immunization.

Guillain-Barré syndrome often causes muscle weakness and sometimes temporary paralysis. Most people who develop the rare syndrome recover.

Such was not the case for a 57-year-old man, The New York Times reported Monday. He had a history of both a heart attack and stroke in the previous 4 years and died in April after vaccination with the J&J vaccine and developing Guillain-Barré.

The new warning comes in the wake of a number of setbacks for the company’s COVID-19 vaccine. On April 13, the FDA and CDC both recommended a 10-day pause on administration of the J&J vaccine after reports of rare blood clot events emerged. In mid-June the FDA requested that Johnson and Johnson discard millions of vaccine doses produced at a manufacturing facility in Baltimore.

The mRNA vaccines from Pfizer/BioNTech and Moderna are not affected by the new FDA warning.

The Biden administration is expected to make a formal announcement of the new warning for the Johnson and Johnson vaccine as early as Tuesday, the Times reports.

Damian McNamara is a staff journalist based in Miami. He covers a wide range of medical specialties, including infectious diseases, gastroenterology, and critical care. Follow Damian on Twitter:  @MedReporter.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn

Products You May Like

Articles You May Like

A promising mRNA vaccine against malaria in mice
CDC Panel Updates Info on Rare Side Effect After J&J Vaccine
Second Dose of COVID Vaccine Safe Even After Allergic Reaction
Scientists developing urine and blood tests to detect brain tumours
Meet Caeleb Dressel, the US Swimmer Who Could Win Up to 7 Olympic Medals in Tokyo

Leave a Reply

Your email address will not be published. Required fields are marked *